Conjupri
Product Images NDC 66992-425

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Conjupri (NDC 66992-425). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Wraser Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Conjupri 01)

Chemical structure of Conjupri shown as a detailed molecular diagram including a chloro-substituted phenyl group, ester and aminoalkoxy substituents, and a succinic acid moiety.*

FDA Label Image

Principal Display Panel (2.5 mg Tablet Bottle Label)

Conjupri 2.5 mg tablets label showing the active ingredient levamlodipine. The label indicates a package size of 30 tablets for prescription use only. It includes manufacturer information from CSPC OuYi Pharmaceutical Co., Ltd., and distributor WraSer Pharmaceuticals LLC, along with storage instructions, dosage strength, and product identification details including NDC 66992-425-30.*

FDA Label Image

Conjupri 03

Conjupri 5 mg levalodipine tablet carton label showing a 30-tablet package from WraSer LLC. The label includes dosage information, storage instructions, and the NDC barcode. It indicates the product is Rx only and child-resistant with a batch expiration area marked by FPO.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.